BANGKOK — National high-tech enterprise MedicalSystem Biotechnology Co., Ltd. presented its total laboratory automation solutions, high-speed biochemistry platforms, and patent-backed cardiovascular diagnostic technologies at International Healthcare Week 2026. The exhibition, held from July 8–10 at the Queen Sirikit National Convention Center (QSNCC), aligns with the Thai government’s policy to establish the nation as a global medical hub.
As one of the few suppliers in the in vitro diagnostic (IVD) industry capable of simultaneously providing diagnostic reagents and instruments, the company utilized the regional platform to showcase its multi-layered product lines spanning biochemistry, chemiluminescence, and advanced lipid subcomponent detection.
The centerpiece of MedicalSystem’s exhibition was its integrated laboratory infrastructure, highlighted by the Total Laboratory Automation System MS-P6. The system supports online integration of analyzers and platforms in both integrated and independent modes, featuring a pre- and post-processing module that connects with multiple analyzers or optional refrigerators.
MS-P6 Technical Specifications:
-
Processing Speeds: Rotated uncapping and automatic capping at a rate of 600 tubes per hour.
-
Centrifugation Capabilities: Maximum speed of 4000 Rpm, accommodating 80 tubes per centrifuge with a throughput of 460 tubes per hour based on a 7-minute cycle time.
-
Tube Management: Supports dumping or drawer loading types, features automatic tube arrangement, reads barcodes quickly, and classifies tubes by specific categories.
-
Physical Dimensions: 900mm × 1100mm × 1400mm.
Beyond processing automation, the company presented its scaled biochemistry platform, which ranges from compact units to high-speed modular systems. The line includes the MS-380P, a compact automated biochemistry analyzer delivering a dual reagent constant speed of 300T/H (600T/H with optional ISE) and featuring on-board hemolysis for HbA1c testing. For mid-to-high volume workloads, the MS-480 and MS-680 deliver dual reagent constant speeds of 400T/H and 680T/H (1360T/H with optional ISE) respectively.
At the high-volume tier, MedicalSystem showcased the MS-1380, operating at a dual reagent constant speed of 800T/H with an equipped ISE ion module, and the MS-2080M, an automated high-speed biochemistry analyzer delivering a dual reagent constant speed of 2000T/H (2750T/H with optional ISE) utilizing dual-arm and dual-needle asynchronous sampling. The flagship automated modular biochemistry analyzer, the MS-L8080, matches the 2000T/H base speed while supporting intelligent modular combinations up to four connections, including biochemistry and immunoassay integration.
MedicalSystem also emphasized its clinical focus on predictive cardiology through its proprietary Vertical Auto Profile (VAP) platform. Following a heavy investment in 2016 to acquire the American Atherotech diagnostic laboratory and its entire patent portfolio, the company brought the mature VAP lipid sub-classes detection technology to market. The platform addresses a critical diagnostic gap: approximately 40% of the general population with normal lipid levels have carotid plaques, and roughly 50% of diagnosed cardiovascular and cerebrovascular disease patients present with normal lipid levels.
By measuring lipoprotein subfractions and particle concentrations, the VAP technology identifies high-risk individuals who show normal standard lipid levels, establishes target molecules for lipid regulation, assesses lipid-lowering medication efficacy, and filters out individuals with elevated lipid levels who maintain a low risk of cardiovascular diseases.
Founded in 2003 in Ningbo, China, and listed on the Shenzhen Stock Exchange GEM in 2015, MedicalSystem operates across in vitro diagnostic reagents, diagnostic instruments, and independent third-party medical diagnostic services. The firm currently holds more than 400 registration certificates for in vitro diagnostic reagents and over 50 registration certificates for diagnostic instruments. Its core corporate development strategy relies on utilizing in vitro diagnostic instruments as the engine, in vitro diagnostic products as the core, and driving the common development of both products and diagnostic services.
The event took place amid a broader regional push led by Thai Prime Minister Anutin Charnvirakul and Public Health Minister Pattana Prompat to expand the local healthcare economy. Organized by Informa Markets (Thailand) and drawing over 1,200 exhibitors and 26,000 global attendees, the mega-platform co-located CPHI South East Asia, World Health Expo (WHX) Bangkok, Medtec Southeast Asia, and the Thailand Medical & Wellness Expo 2026.
“Hosting this event is not only a proud milestone for Thailand but also directly aligns with the government’s key policy. We are fully committed to driving the medical and healthcare industry as a key new growth engine. Our goal is clear: to position Thailand as a world-class Global Medical Hub by raising product standards, driving innovative healthcare services, and boosting economic value within the Healthcare Economy across all dimensions,” the prime minister said.
He added that the government believes today’s economic challenges cannot be addressed by any country alone. “True success requires international cooperation,” he said. “This event demonstrates collaboration across the entire medical industry supply chain, from upstream to downstream. The business negotiations and partnerships established here will help create greater stability, prosperity and sustainability through tangible cooperation in healthcare and technology.”
Public Health Minister Pattana Prompat said the event is far more than a conventional trade exhibition. “It is an important mechanism for translating the government’s policy into tangible outcomes through collaboration between the public and private sectors to build a stronger, more prosperous and sustainable healthcare economy for Thailand,” he said.
Mr. Manu Leopairote, Chairman of Informa Markets (Thailand), noted that the event incorporates over 200 specialized academic seminars to anchor sustainable growth in the ASEAN region. “In addition to showcasing cutting-edge innovations across the four exhibitions, we place strong emphasis on advancing professional knowledge through more than 200 specialized seminar sessions, many of which offer Continuing Medical Education (CME) credits,” Manu said. “This strategy will help strengthen the healthcare industries of Thailand and ASEAN and support their sustainable growth on the global stage. International Healthcare Week 2026 is more than an exhibition-it is an important springboard that enables partners across the industry to demonstrate Thailand’s strengths and elevate the country’s healthcare industry in the eyes of the world.”
Leave a Reply